Latest research: Immune globulin shows promise for severe Zika thrombocytopenia
December 10th, 2018Elizabeth A Van Dyne, Paige Neaterour, Aidsa Rivera, Melissa Bello-Pagan, Laura Adams, Jorge Munoz-Jordan, Priscilla Baez, Myriam Garcia, Stephen H Waterman, Nimia Reyes, Lisa C Richardson, Brenda Rivera-Garcia, Tyler M Sharp; Incidence and Outcome of Severe and Non-severe Thrombocytopenia Associated with Zika Virus Infection — Puerto Rico, 2016, Open Forum Infectious Diseases, , ofy325, https://doi.org/10.1093/ofid/ofy325
“…..Of 37,878 patients with ZIKV infection, 47 (0.1%) had thrombocytopenia in the absence of an alternative etiology (1.4 cases/100,000 population), including 12 with severe thrombocytopenia. Most patients with thrombocytopenia were adult (77%) and male (53%). Platelet nadir occurred a median of six (range: 1–16) and five (range: 0–34) days after symptom onset for patients with severe and non-severe thrombocytopenia, respectively. Among patients with severe thrombocytopenia, all had bleeding, 33% were admitted to the ICU, and 8% died; 50% were treated for ITP. Among five patients with severe thrombocytopenia who received intravenous immunoglobulin, median platelet count increase was 112 X 10 9/L (range: 65–202 X 10 9/L). In contrast, among four patients who received platelet transfusion, median increase in platelet count was 8.5 X 10 9/L (range: -6–52 x 10 9/L)……”
